MY01 Inc. Receives FDA Clearance for the MY01 Continuous Compartment Pressure Monitor as an Aid in Diagnosis of Compartment Syndrome
- MY01
MONTREAL, May 6, 2021 /PRNewswire/ – MY01’s device helps diagnose acute compartment syndrome (ACS), a relatively common and potentially lethal muscle condition notably suffered by Tiger Woods in his car accident last February. Because current diagnostic tools rely on a patient’s inherently subjective pain description, ACS diagnosis is often misdiagnosed or missed entirely and is the main cause of lost lawsuits against orthopedic surgeons in the U.S. Read more…
Related Reading
Resource / Business Development
Accelerated access to novel cancer therapies at Moores Cancer Center
November 27, 2024
Learn how the EY Clinical Trial Fast Lane solution helps jumpstart clinical trials in 45 to 60 working days through rapid performance of functional services, deep understanding of clinical trial operations, and more.
Event / Regulatory Affairs
Medical Device Submissions Workshops – Premarket Approval (PMA)
8:30 am – 4:30 pm ET
February 6-7, 2025
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
Event / Regulatory Affairs
Medical Device Submissions Workshops – Investigational Device Exemption (IDE)
8:30 am – 5:15 pm ET
February 5, 2025
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
Event / China / Regulatory Affairs
China Regulatory Workshop
November 19, 2024 | 11:30 AM – 6:30 PM PT November 20, 2024 | 8:15 AM – 4:00 PM PT
Get the latest on new policy updates and guidance for the clinical evaluation of medical devices.
Event / Regulatory Affairs
Medical Device Submissions Workshops – 510(k) and De Novo
8:30 am – 4:15 pm ET
February 3-4, 2025
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
News / Regulatory Affairs
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
July 31, 2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
Event / Digital Health / Regulatory Affairs
AdvaMed Cybersecurity Summit
November 13, 2024
8:15 AM – 6:00 PM
Join us in Washington, D.C. for our Cybersecurity Summit that will address the future of medical device cybersecurity and changes in the industry landscape related to FDA requirements.
Resource / Regulatory Affairs
MedTech Reimbursement Playbook
July 17, 2024
Learn the basic principles of how medical technologies are covered and paid by insurers and the challenges medtech companies face.